These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28814435)

  • 1. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
    Alexander BM; Ba S; Berger MS; Berry DA; Cavenee WK; Chang SM; Cloughesy TF; Jiang T; Khasraw M; Li W; Mittman R; Poste GH; Wen PY; Yung WKA; Barker AD;
    Clin Cancer Res; 2018 Feb; 24(4):737-743. PubMed ID: 28814435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.
    Trippa L; Lee EQ; Wen PY; Batchelor TT; Cloughesy T; Parmigiani G; Alexander BM
    J Clin Oncol; 2012 Sep; 30(26):3258-63. PubMed ID: 22649140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
    Rahman R; Trippa L; Lee EQ; Arrillaga-Romany I; Fell G; Touat M; McCluskey C; Wiley J; Gaffey S; Drappatz J; Welch MR; Galanis E; Ahluwalia MS; Colman H; Nabors LB; Hepel J; Elinzano H; Schiff D; Chukwueke UN; Beroukhim R; Nayak L; McFaline-Figueroa JR; Batchelor TT; Rinne ML; Kaley TJ; Lu-Emerson C; Mellinghoff IK; Bi WL; Arnaout O; Peruzzi PP; Haas-Kogan D; Tanguturi S; Cagney D; Aizer A; Doherty L; Lavallee M; Fisher-Longden B; Dowling S; Geduldig J; Watkinson F; Pisano W; Malinowski S; Ramkissoon S; Santagata S; Meredith DM; Chiocca EA; Reardon DA; Alexander BM; Ligon KL; Wen PY
    J Clin Oncol; 2023 Dec; 41(36):5524-5535. PubMed ID: 37722087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of biomarkers in phase II studies of recurrent glioblastoma.
    Jue TR; Hovey E; Davis S; Carleton O; McDonald KL
    Tumour Biol; 2015 Jan; 36(1):153-62. PubMed ID: 25534238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I-III Studies.
    Cho NS; Wong WK; Nghiemphu PL; Cloughesy TF; Ellingson BM
    Curr Oncol Rep; 2023 Sep; 25(9):1047-1055. PubMed ID: 37402043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
    Zhu P; Zhu JJ
    Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
    Gainer JL; Sheehan JP; Larner JM; Jones DR
    J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
    Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
    Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Necroptosis: a novel therapeutic target for glioblastoma.
    Jiang YG; Peng Y; Koussougbo KS
    Med Hypotheses; 2011 Mar; 76(3):350-2. PubMed ID: 21075544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches.
    Gilbert MR
    Semin Oncol; 2011 Dec; 38 Suppl 4():S21-33. PubMed ID: 22078645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma multiforme: evidence-based approach to therapy.
    Nicholas MK
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S23-7. PubMed ID: 18076314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel trial designs in neuro-oncology.
    Song KW; Wen PY
    Curr Opin Neurol; 2023 Dec; 36(6):571-578. PubMed ID: 37865854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Directions in the Treatment of Glioblastoma.
    Reitman ZJ; Winkler F; Elia AEH
    Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive randomization versus interim monitoring.
    Freidlin B; Korn EL
    J Clin Oncol; 2013 Mar; 31(7):969-70. PubMed ID: 23341515
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.